Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 33.48 EUR 0.09% Market Closed
Market Cap: 18.9B EUR
Have any thoughts about
Fresenius SE & Co KGaA?
Write Note

Net Margin
Fresenius SE & Co KGaA

-1.8%
Current
2%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.8%
=
Net Income
-383m
/
Revenue
21.9B

Net Margin Across Competitors

Country DE
Market Cap 18.8B EUR
Net Margin
-2%
Country US
Market Cap 75.6B EUR
Net Margin
1%
Country US
Market Cap 77.9B USD
Net Margin
1%
Country US
Market Cap 56B USD
Net Margin
1%
Country DE
Market Cap 26B EUR
Net Margin
3%
Country US
Market Cap 19.3B USD
Net Margin
3%
Country US
Market Cap 16.9B USD
Net Margin
-2%
Country US
Market Cap 17.1B USD
Net Margin
9%
Country DE
Market Cap 13B EUR
Net Margin
3%
Country US
Market Cap 12.7B USD
Net Margin
7%
Country AU
Market Cap 13.2B AUD
Net Margin
6%
No Stocks Found

Fresenius SE & Co KGaA
Glance View

Market Cap
18.9B EUR
Industry
Health Care

Fresenius SE & Co. KGaA, a titan in the global healthcare sector, traces its origins to a humble pharmacy in Frankfurt, Germany, in 1912. Since then, the company has evolved into a multifaceted healthcare conglomerate, positioning itself prominently in four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Each segment synergizes to form a comprehensive healthcare ecosystem. Fresenius Medical Care, the crown jewel of the group, stands as the world’s leading provider of products and services for individuals with renal diseases. This division, with a focus on dialyzing patients suffering from chronic kidney failure, operates a vast network of dialysis clinics and manufactures dialysis machines and related products that account for a significant portion of its income. Meanwhile, Fresenius Kabi, the pharmaceutical and medical device division, specializes in lifesaving drugs and technologies for critically and chronically ill patients. This division thrives on providing clinical nutrition, infusion therapy, and generics, positioning itself as a critical player in hospitals worldwide. Fresenius Helios is acknowledged as Europe's largest private hospital operator, managing a vast array of healthcare facilities that deliver inpatient and outpatient care, ensuring a steady stream of revenue through diverse healthcare services. Lastly, Fresenius Vamed provides a wide range of services for healthcare facilities, from project development and construction to full operational management, allowing the company to gain financial benefits from turnkey hospital solutions and infrastructure development. Through these concerted efforts, Fresenius SE & Co. KGaA cements its role as a key stakeholder in the global healthcare market, generating substantial revenues while addressing diverse medical needs across the globe.

FRE Intrinsic Value
73.78 EUR
Undervaluation 55%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.8%
=
Net Income
-383m
/
Revenue
21.9B
What is the Net Margin of Fresenius SE & Co KGaA?

Based on Fresenius SE & Co KGaA's most recent financial statements, the company has Net Margin of -1.8%.